Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
MWN-AI** Summary
Recursion (Nasdaq: RXRX), a prominent clinical stage TechBio company focused on decoding biology to enhance lives, will provide its fourth quarter and full year 2025 business updates and financial results on February 25, 2026, before the market opens. The company will also host a (L)earnings call at 8:00 AM ET, which will be accessible through a live stream on various platforms, including Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public can engage with the company by submitting questions in advance via a provided link.
Recursion is recognized for its innovative Recursion OS, a platform that integrates diverse technologies to generate vast proprietary biological and chemical datasets, translating complex biological relationships through machine-learning algorithms. This advanced capability allows the company to conduct up to millions of experiments weekly and operate one of the world's most powerful supercomputers, uniting technology, biology, and chemistry to advance medical research and drug discovery.
Headquartered in Salt Lake City, Recursion is a key player in the BioHive life sciences collective and has additional offices in Montréal, New York, London, and Oxford. The company’s forward-looking statements reflect its plans regarding financial performance, collaborations, and drug development, but caution is advised as the actual outcomes may vary due to various risks and uncertainties inherent in pharmaceutical research and development.
Investors and interested parties can find more information on Recursion’s activities and updates on their official website and through their social media channels. Those seeking more details can contact the media at media@recursion.com or reach out to investor relations at investor@recursion.com.
MWN-AI** Analysis
As Recursion (NASDAQ: RXRX) prepares to unveil its fourth quarter and full-year 2025 results on February 25, 2026, investors should be poised for critical insights into its financial health and strategic direction. The company's innovative approach to leveraging machine learning in biology positions it at the forefront of the TechBio sector, which is evolving rapidly with substantial growth potential.
Market analysts will be keenly focused on several key indicators in the upcoming earnings call. First, it's essential to assess Recursion's revenue growth and progress with its clinical programs, especially considering the inherent risks associated with drug development. In previous quarters, discussions surrounding early and late-stage therapies were pivotal. With a powerful supercomputing backbone and extensive experimental capabilities, market participants will scrutinize the efficiency and progress of its drug discovery efforts.
Moreover, given recent trends across biotechnology, any commentary on partnerships or collaborations will influence investor sentiment significantly. Strong alliances can enhance capital stability and accelerate breakthroughs, but potential setbacks in regulatory approvals or clinical trial outcomes are critical risk factors that could lead to volatility in stock performance.
Investors should also be attentive to guidance for 2026, especially in terms of anticipated milestones and fundraising initiatives. Recursion's future success hinges on its ability to maintain its experimental scale while effectively navigating economic headwinds, including inflation impacts and labor market challenges.
The market for TechBio solutions is increasingly competitive, and thus, how Recursion differentiates itself in the landscape—particularly through data-driven insights—will bear weight on its stock trajectory post-earnings. Timely engagement in the Q&A segment could reveal management's perspectives on long-term strategy, which is likely to invigorate or dampen interest depending on the responses.
In conclusion, with its innovative capabilities and strategic positioning, Recursion holds promise for growth; however, investor caution is warranted as they await concrete updates on its financial and operational standing.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets.
Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the filing of quarterly earnings; the occurrence and timing of an investor call; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contactmedia@recursion.comInvestor Contactinvestor@recursion.com
FAQ**
What specific advances or milestones in Recursion Pharmaceuticals Inc. RXRX's drug discovery platform should investors anticipate in the upcoming earnings call on February 25, 2026?
Can you provide updates on any ongoing clinical trials or preclinical programs that Recursion Pharmaceuticals Inc. RXRX is currently conducting, and how they align with overall business objectives?
How does Recursion Pharmaceuticals Inc. RXRX plan to leverage its massive datasets and computational capabilities to address potential challenges in the pharmaceutical research and development landscape?
What strategies is Recursion Pharmaceuticals Inc. RXRX employing to sustain growth and manage risks associated with drug commercialization, particularly amid macroeconomic uncertainties?
**MWN-AI FAQ is based on asking OpenAI questions about Recursion Pharmaceuticals Inc. (NASDAQ: RXRX).
NASDAQ: RXRX
RXRX Trading
4.52% G/L:
$3.405 Last:
9,334,431 Volume:
$3.35 Open:
